Relypsa

Relypsa, Inc. is a privately held, development-stage biopharmaceutical company focused on the discovery and development of novel non-absorbed polymeric drugs for significant applications in cardiovascular and renal diseases. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the treatment of hyperkalemia. Relypsa is committed to discovering additional product candidates through its proprietary polymer platform.